Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Switzerland expecting 1 million COVID vaccine doses from Moderna, Pfizer in March

Published 03/10/2021, 04:26 PM
Updated 03/10/2021, 04:30 PM
© Reuters. Vials of Pfizer vaccine against the coronavirus disease (COVID-19) are seen at the Messe Luzern fairground's vaccination center

© Reuters. Vials of Pfizer vaccine against the coronavirus disease (COVID-19) are seen at the Messe Luzern fairground's vaccination center

(This March 9 story corrects figure to 900,000 shots administered, not 900,000 people getting a first shot in paragraph 2)

By John Miller

ZURICH (Reuters) - Switzerland expects to get 1 million vaccine doses from Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) this month, a senior Federal Health Ministry vaccine official said on Tuesday, after receiving some 1.1 million in January and February.

"We have steadily rising delivery volumes every month, and we expect that will help us reach our targets," Nora Kronig, who heads the health ministry's vaccine logistics effort, adding 900,000 people have so far had their first shot and 320,000 a second booster.

The planned March deliveries exceed initial expectations, and Kronig said they'll be sufficient to make up for slightly lower volumes that arrived last month.

Switzerland expects to vaccinate all of its 8.6 million residents who want a COVID-19 shot by summer, and Kronig's latest comments suggest the nation is on track, especially with potential approvals of new vaccines in coming weeks. Mass vaccinations beyond older people are due to begin in the second quarter.

New infections reported on Tuesday totaled 1,378 cases, well below the 10,000-plus record from Nov. 2. Another 13 deaths were reported.

Even so, cases have slightly risen since mid-February, driven by accelerating infections with new variants of the virus, leaving the pandemic's trajectory in coming weeks uncertain, a scientist on Switzerland's COVID-19 task force said.

Task force member Martin Ackermann, a biologist at the Swiss Federal Institute of Technology in Zurich, urged more testing, continued hygiene measures -- and aggressive vaccinations as more shots arrive.

© Reuters. Vials of Pfizer vaccine against the coronavirus disease (COVID-19) are seen at the Messe Luzern fairground's vaccination center

"At this time, the number of people who have gotten shots is still too small to have a significant influence on new infections," Ackermann said. "Speeding up the pace will pay off, once more shots become available."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.